PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

22 Feb 2018 15:40

RNS Number : 7015F
Silence Therapeutics PLC
22 February 2018
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Silence Therapeutics PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

ING Groep N.V.

City and country of registered office (if applicable)

Amsterdam / Netherlands

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

21-02-2018

6. Date on which issuer notified (DD/MM/YYYY):

22-02-2018

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

5.06%

5.06%

70,021,624

Position of previous notification (if

applicable)

4.94%

4.94%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00B9GTXM62

3,543,509

5.06%

SUBTOTAL 8. A

3,543,509

5.06%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

ING Groep N.V.

5.06%

5.06%

ING Bank N.V.

5.06%

5.06%

10. In case of proxy voting, please identify:

Name of the proxy holder

n.a.

The number and % of voting rights held

n.a.

The date until which the voting rights will be held

n.a.

11. Additional informationxvi

 

Place of completion

Amsterdam

Date of completion

22 February 2018

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUUOVRWRAUUAR
Date   Source Headline
21st Mar 20127:00 amPRNUnaudited Preliminary Results
19th Mar 20127:00 amPRNNotification of Preliminary Results
10th Feb 20127:00 amPRNSilence Therapeutics Announces Board Changes and New CEO
27th Jan 20124:40 pmRNSSecond Price Monitoring Extn
27th Jan 20124:35 pmRNSPrice Monitoring Extension
26th Jan 20127:00 amPRNTR-1: Notifications of Major Interest in Shares
23rd Jan 20127:00 amPRNTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
9th Jan 20127:00 amPRNSilence signs collaboration with miRagen Therapeutics
6th Jan 20127:00 amPRNResearch and Development Collaboration Update
30th Dec 20117:00 amPRNTotal Voting Rights
20th Dec 20114:40 pmRNSSecond Price Monitoring Extn
20th Dec 20114:35 pmRNSPrice Monitoring Extension
20th Dec 20117:00 amPRNAdditional Listing
12th Dec 20117:00 amPRNPositive Response by USPTO
9th Dec 20114:40 pmRNSSecond Price Monitoring Extn
9th Dec 20114:35 pmRNSPrice Monitoring Extension
7th Dec 20111:27 pmPRNPositive outcome from oral hearing at Patent Office
22nd Nov 20114:40 pmRNSSecond Price Monitoring Extn
22nd Nov 20114:35 pmRNSPrice Monitoring Extension
8th Nov 20117:00 amPRNSilence Therapeutics provides update
24th Oct 20117:00 amPRNCollaboration with Mirna Therapeutics
14th Oct 20117:00 amPRNGrant of options
3rd Oct 20117:00 amPRNDirectors’ share purchases
21st Sep 20117:00 amPRNAppointment of Chief Business Officer
21st Sep 20117:00 amPRNInterim Results for the Six Months Ended 30 June 2011
20th Sep 20117:00 amPRNAppointment of Chief Executive Officer
14th Sep 201110:32 amPRNNotice of Results
13th Sep 20114:40 pmRNSSecond Price Monitoring Extn
13th Sep 20114:35 pmRNSPrice Monitoring Extension
12th Sep 20119:24 amPRNSilence & InteRNA Technologies collaboration
8th Sep 20114:40 pmRNSSecond Price Monitoring Extn
8th Sep 20114:35 pmRNSPrice Monitoring Extension
5th Sep 20114:40 pmRNSSecond Price Monitoring Extn
5th Sep 20114:35 pmRNSPrice Monitoring Extension
1st Sep 20114:40 pmRNSSecond Price Monitoring Extn
1st Sep 20114:35 pmRNSPrice Monitoring Extension
31st Aug 20114:40 pmRNSSecond Price Monitoring Extn
31st Aug 20114:35 pmRNSPrice Monitoring Extension
26th Aug 20114:40 pmRNSSecond Price Monitoring Extn
26th Aug 20114:35 pmRNSPrice Monitoring Extension
23rd Aug 20114:41 pmRNSSecond Price Monitoring Extn
23rd Aug 20114:35 pmRNSPrice Monitoring Extension
22nd Aug 20114:40 pmRNSSecond Price Monitoring Extn
22nd Aug 20114:35 pmRNSPrice Monitoring Extension
18th Aug 20114:41 pmRNSSecond Price Monitoring Extn
18th Aug 20114:35 pmRNSPrice Monitoring Extension
12th Aug 20114:40 pmRNSSecond Price Monitoring Extn
12th Aug 20114:35 pmRNSPrice Monitoring Extension
11th Aug 20114:40 pmRNSSecond Price Monitoring Extn
11th Aug 20114:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.